Equity Profile

LEGN

Legend Biotech Corporation

Health CareBiotechnology$3.9B

Dec1Thu

Pre-Earnings Brief

UpcomingQ2-2024After Close5:00 PM EST

Company Snapshot

Legend Biotech Corporation is a biotechnology company focused on developing innovative cell therapies for cancer treatment. Operating in the healthcare sector, its advancements could significantly impact patient outcomes and the overall landscape of cancer therapies.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its products effectively.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q2-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

In the last quarter, Legend Biotech reported an EPS of -$0.16, which was better than the expected -$0.29, resulting in a positive surprise. However, there was no revenue reported, leaving some uncertainty about its financial performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts and investors are cautiously optimistic about Legend Biotech's upcoming earnings, particularly after a surprise in the last quarter. However, the lack of revenue guidance raises concerns about future performance.

Bull Case

If Legend Biotech can demonstrate strong advancements in its therapies and report better-than-expected EPS, it could lead to increased investor confidence and a positive stock reaction.

Bear Case

Conversely, if the company fails to provide clear revenue guidance or reports worse-than-expected EPS, it may lead to a negative market reaction and concerns about its growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements in cell therapies can the company report this quarter?

Investors will weigh this heavily as it could indicate the company's future growth potential and market competitiveness.

Will there be any guidance on revenue for the upcoming quarters?

Clear revenue guidance is crucial for investor confidence and could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Legend Biotech's therapies to gain traction in the market, especially given recent advancements in the biotech sector.

Supporting Evidence

The company's recent EPS surprise indicates stronger-than-expected performance, which may not be fully reflected in current valuations.

Options pricing suggests a significant move, indicating that traders are anticipating more volatility than the consensus may suggest.

Key Risk

If the company provides strong guidance or unexpected positive news on its therapies, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis this quarter revolves around the company's ability to show progress in its therapies and provide clarity on future revenue.

Bull Confirmed If

Reporting an EPS better than -$0.16 and providing positive revenue guidance would confirm the bull case.

Bear Confirmed If

Reporting an EPS worse than -$0.29 without clear revenue guidance would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.82%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±14.8% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

85.1%

Calls (20K)P/C Ratio: 0.10Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations and raises guidance, history suggests a positive stock reaction, averaging a +1.71% move.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted reaction as investors digest the commentary.

Miss

If the company misses expectations, history suggests a potential downside move, averaging around -6.91%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of cell therapy trials and their potential market impact.
2Management's outlook on revenue growth for the next few quarters.
3Details on partnerships or collaborations that could enhance product development.
4Insights into competitive positioning within the biotechnology sector.
5Comments on regulatory progress or challenges related to product approvals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Elbit Systems Ltd.

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its products effectively.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q2-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Legend Biotech can demonstrate strong advancements in its therapies and report better-than-expected EPS, it could lead to increased investor confidence and a positive stock reaction.

Bear Case

Conversely, if the company fails to provide clear revenue guidance or reports worse-than-expected EPS, it may lead to a negative market reaction and concerns about its growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements in cell therapies can the company report this quarter?

Investors will weigh this heavily as it could indicate the company's future growth potential and market competitiveness.

Will there be any guidance on revenue for the upcoming quarters?

Clear revenue guidance is crucial for investor confidence and could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Legend Biotech's therapies to gain traction in the market, especially given recent advancements in the biotech sector.

Supporting Evidence

The company's recent EPS surprise indicates stronger-than-expected performance, which may not be fully reflected in current valuations.

Options pricing suggests a significant move, indicating that traders are anticipating more volatility than the consensus may suggest.

Key Risk

If the company provides strong guidance or unexpected positive news on its therapies, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis this quarter revolves around the company's ability to show progress in its therapies and provide clarity on future revenue.

Bull Confirmed If

Reporting an EPS better than -$0.16 and providing positive revenue guidance would confirm the bull case.

Bear Confirmed If

Reporting an EPS worse than -$0.29 without clear revenue guidance would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.82%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±14.8% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

85.1%

Calls (20K)P/C Ratio: 0.10Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations and raises guidance, history suggests a positive stock reaction, averaging a +1.71% move.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted reaction as investors digest the commentary.

Miss

If the company misses expectations, history suggests a potential downside move, averaging around -6.91%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of cell therapy trials and their potential market impact.
2Management's outlook on revenue growth for the next few quarters.
3Details on partnerships or collaborations that could enhance product development.
4Insights into competitive positioning within the biotechnology sector.
5Comments on regulatory progress or challenges related to product approvals.